Subunits of ARID1 serve as novel biomarkers for the sensitivity to immune checkpoint inhibitors and prognosis of advanced non-small cell lung cancer

INTRODUCTION: Patients with advanced non-small cell lung cancer (NSCLC) benefit from treatment with immune checkpoint inhibitors (ICIs). Biomarkers such as programmed death-ligand 1 (PD-L1), the tumor mutational burden (TMB) and the mismatch repair (MMR) status are used to predict the prognosis of I...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Dantong, Tian, Lu, Zhu, Yan, Wo, Yang, Liu, Qiaoling, Liu, Shihai, Li, Hong, Hou, Helei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7425138/
https://www.ncbi.nlm.nih.gov/pubmed/32791957
http://dx.doi.org/10.1186/s10020-020-00208-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7425138/
https://www.ncbi.nlm.nih.gov/pubmed/32791957
http://dx.doi.org/10.1186/s10020-020-00208-9

Ejemplares similares